Brief: Lidds Announces Data On Liproca Depot From Open Label Extension Study

Lidds AB

30/09/2020 07:40

Sept 30 (Reuters) - Lidds AB  LIDDS.ST :
    * REG-LIDDS ANNOUNCES DATA ON LIPROCA DEPOT FROM OPEN LABEL
EXTENSION STUDY
    * RESULTS SHOWED THAT 50 % OF PATIENTS REMAINED AT LOW PSA
LEVELS
FOR AT LEAST 10 MONTHS FROM THEIR FIRST LIPROCA® DEPOT INJECTION
AND WERE THEREFORE NOT TREATED WITH A SECOND INJECTION
    * RESULTS ARE ENCOURAGING FOR PROSTATE CANCER PATIENTS
PLACED
UNDER ACTIVE SURVEILLANCE GIVEN THAT THEY INDICATE A
SUBSTANTIALLY LONGER EFFECT
    * LIPROCA DEPOT HAS NO HORMONAL SIDE EFFECTS AND DOES NOT
ALTER
ERECTILE FUNCTION, WHICH ARE SEEN WITH CONVENTIONAL
ANTI-ANDROGEN TREATMENT

Source text for Eikon:  ID:nGNEc7C8tG 
Further company coverage:  LIDDS.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))